← Leaderboards
Derek E Byers
Washington University
$299,990
Attributed
$1,199,961
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $544.9K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,199,961 · 2
By mechanism
R61$655,076 · 1
R33$544,885 · 1
Top collaborators
- Andrew Eric Gelman3 shared
- Charles Goss3 shared
- Ramsey Hachem3 shared
Most similar at Washington University
Same institution · by research overlap
- Ramsey Hachem$6,763,198
- J Evan Sadler$26,812,449
- Thalachallour Mohanakumar$18,846,664
- Andrew Eric Gelman$12,797,349
- David D Tran$4,389,335
Others in their field
Other Rising Stars on “Adrenal Cortex Hormones”
- Katherine Rivera-Spoljaric · Washington University$4,587,360
- Kenneth Schultz · Trethera Corporation$2,651,607
- Nuria Tubau Juni · Biotherapeutics, Inc.$2,445,560
- Dawn Dawn Bitz · Lazzaro Medical, Inc.$2,427,831
- Teodora Nicola · Resbiotic, Inc.$2,290,381
- Wansu Chen · Kaiser Foundation Research Institute$2,249,367
Research focus
Adrenal Cortex HormonesAffinityAllograftingAllograft RejectionAntibodiesAntibody FormationAntibody-Mediated RejectionAntibody TherapyAntithymoglobulinB Cell DifferentiationBindingBiologicalCause Of DeathCd4 Positive T LymphocytesCd8-Positive T-LymphocytesCell CountCell Free DnaCell ProliferationCellsCessation Of LifeCharacteristicsChronicClinical TrialsAcute
Grant awards (3)
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation$544,885
R33 · FY2025 · HL
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation$283,671
R61 · FY2024 · HL
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation$371,405
R61 · FY2023 · HL